Monopar Therapeutics
MNPR Nasdaq
SEC CIK 1645469
Follow Monopar Therapeutics
Weekly email: filings, results
Revenue, last quarter
$0
Net income
−$6.2M
−80.3% vs same quarter last year
EPS, diluted
−$0.72
−50% vs same quarter last year
Operating cash flow
−$6.2M
−156.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $0 | −$13.7M |
| FY24 | $0 | −$15.6M |
| FY23 | - | −$8.4M |
| FY22 | - | −$10.5M |
| FY21 | - | −$9.1M |
| FY20 | - | −$6.3M |
| FY19 | $0 | −$4.2M |
| FY18 | $0 | −$3.2M |
| FY17 | $0 | −$16.6M |
| FY16 | $0 | −$1.2M |
| FY15 | - | - |